Demographics, Prior Therapies, and Reasons for Cemiplimab Treatment: Prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) Study in Patients with Advanced Cutaneous Squamous Cell Carcinoma. J of Skin [Internet]. 2020 Oct. 27 [cited 2025 Apr. 19];4(6):s125. Available from: https://skin.dermsquared.com/skin/article/view/1098